Cochrane · systematic review · CD006320
Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease
Lev‐Tzion, R, Griffiths, AM, Ledder, O, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 40%Low 0 · 0%Moderate 3 · 60%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: Crohn's disease patients in remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse rate at one year (all studies) | RR 0.77 [0.61, 0.98] | 6 studies · 1039 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Relapse rate at one year (sensitivity analysis of Belluzi 1996) | RR 0.77 [0.64, 0.93] | 5 studies · 904 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Relapse rate at one year (only EPIC studies) | RR 0.88 [0.74, 1.05] | 2 studies · 738 participants | Moderate Downgraded: imprecision |
Adverse events rate‐Diarrhea | RR 1.36 [1.01, 1.84] | 4 studies · 862 participants | Moderate Downgraded: imprecision |
Adverse events rate‐ Upper GI (nausea, vomiting, halitosis, heartburn, dyspepsia, dysgeusia and bloating) | RR 1.98 [1.38, 2.85] | 5 studies · 999 participants | Moderate Downgraded: imprecision |